Takashi Ishikawa
Overview
Explore the profile of Takashi Ishikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
478
Citations
5510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagerty B, Sato T, Wu R, Ishikawa T, Takabe K
Ann Surg Oncol
. 2025 Mar;
PMID: 40080368
Background: Mesothelin (MSLN), a cell surface glycoprotein, is commonly expressed in several cancers, including 40% of triple negative breast cancer (TNBC) cases. Although its cellular or physiologic functions remain unclear,...
2.
Hikino K, Shoji K, Saito J, Fukunaga K, Liu X, Matsui T, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 40001258
Aims: The influence of CYP2C19 polymorphisms on voriconazole plasma concentrations is recognized, but its extent, other contributing factors and risks for adverse reactions remain under-explored. Methods: This study focused on...
3.
Kawashima K, Narui K, Nishikawa A, Sasamoto M, Oshi M, Adachi S, et al.
Breast Cancer
. 2025 Feb;
PMID: 39976837
Background: The MonarchE trial demonstrated the additional benefit of abemaciclib as an adjuvant endocrine therapy for high-risk patients with hormone receptor (HR)-positive HER2-negative breast cancer. Meanwhile, the ACOSOG Z0011 trial...
4.
Sawatsubashi T, Sakakibara K, Saito K, Yagi R, Ishikawa T, Nakatsuka H, et al.
Gan To Kagaku Ryoho
. 2025 Feb;
51(13):1452-1454.
PMID: 39948887
The patient, a 70-year-old post-menopausal woman diagnosed with cT2N0M0, Stage ⅡA, triple-negative breast cancer (TNBC), received neoadjuvant chemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab. After 3 courses of chemotherapy, the...
5.
Sawatsubashi T, Sakakibara K, Saito K, Yagi R, Ishikawa T, Nakatsuka H, et al.
Gan To Kagaku Ryoho
. 2025 Feb;
51(13):1449-1451.
PMID: 39948886
The patient was a 38-year-old premenopausal woman. Under the diagnosis of left breast cancer with cT2N3cM1(OSS), Stage Ⅳ, Luminal B like, we started treatment with anastrozole, leuprorelin, abemaciclib and denosumab....
6.
Yamada M, Chishima T, Ishikawa T, Narui K, Sugae S, Tonellato P, et al.
BMC Cancer
. 2025 Feb;
25(1):206.
PMID: 39910468
Background: Each breast cancer (BC) risk factor has different effects on different populations. However, there are no well-studied and validated BC risk prediction models for Japanese women. We developed accessible...
7.
Tabata K, Miyazaki O, Imai A, Okamoto R, Miyasaka M, Tsutsumi Y, et al.
Radiol Case Rep
. 2025 Feb;
20(3):1784-1789.
PMID: 39898337
The BCG vaccine is effective in preventing severe tuberculosis infections in infants and young children, and it is commonly administered in Japan to those aged between 5 to 8 months....
8.
Yee G, Wu R, Oshi M, Endo I, Ishikawa T, Takabe K
World J Oncol
. 2025 Jan;
16(1):16-29.
PMID: 39850523
Background: Peritumoral lidocaine infiltration prior to excision is associated with better survival in breast cancer (BC), which led us to hypothesize that innervation to the tumor affects its biology and...
9.
Sharma P, Chida K, Wu R, Tung K, Hakamada K, Ishikawa T, et al.
World J Oncol
. 2025 Jan;
16(1):120-130.
PMID: 39850522
Background: Vascular endothelial growth factor-A (VEGFA) is a key inducer of angiogenesis, responsible for generating new blood vessels in the tumor microenvironment (TME) and facilitating metastasis. Notably, Avastin, which targets...
10.
Ikuse T, Matsui T, Shoji K, Kono N, Yamada M, Ogimi C, et al.
Euro Surveill
. 2025 Jan;
30(1.
PMID: 39790073
In 2022-23, several European countries reported paediatric acute liver failure (ALF) with enterovirus infection. In August-November 2024, three neonatal cases of ALF with echovirus 11 (E11) were reported in Tokyo,...